Abstract
Summary
Phenylketonuria Medication refers to drugs and treatments used to manage phenylketonuria, a genetic disorder that impairs the body's ability to process the amino acid phenylalanine. PKU medications are designed to help regulate phenylalanine levels in the blood to prevent cognitive and developmental issues associated with the disorder.
The global market for Phenylketonuria Medication was estimated to be worth US$ 8 million in 2023 and is forecast to a readjusted size of US$ 11 million by 2030 with a CAGR of 4.6% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Phenylketonuria Medication, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Phenylketonuria Medication by region & country, by Type, and by Application.
The Phenylketonuria Medication market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phenylketonuria Medication.
Market Segmentation
By Company
Biomarin
Vitaflo
Mead Johnson
Nutricia
Abbott
Dr. Schär
Prominmetabolics
Cambrooke
Juvela
Firstplay Dietary
PKU Perspectives
Segment by Type:
Kuvan
Palynziq
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Phenylketonuria Medication manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Phenylketonuria Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Phenylketonuria Medication in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Phenylketonuria Medication was estimated to be worth US$ 8 million in 2023 and is forecast to a readjusted size of US$ 11 million by 2030 with a CAGR of 4.6% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Phenylketonuria Medication, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Phenylketonuria Medication by region & country, by Type, and by Application.
The Phenylketonuria Medication market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phenylketonuria Medication.
Market Segmentation
By Company
Biomarin
Vitaflo
Mead Johnson
Nutricia
Abbott
Dr. Schär
Prominmetabolics
Cambrooke
Juvela
Firstplay Dietary
PKU Perspectives
Segment by Type:
Kuvan
Palynziq
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Phenylketonuria Medication manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Phenylketonuria Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Phenylketonuria Medication in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Phenylketonuria Medication Product Introduction
1.2 Global Phenylketonuria Medication Market Size Forecast
1.3 Phenylketonuria Medication Market Trends & Drivers
1.3.1 Phenylketonuria Medication Industry Trends
1.3.2 Phenylketonuria Medication Market Drivers & Opportunity
1.3.3 Phenylketonuria Medication Market Challenges
1.3.4 Phenylketonuria Medication Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Phenylketonuria Medication Players Revenue Ranking (2023)
2.2 Global Phenylketonuria Medication Revenue by Company (2019-2024)
2.3 Key Companies Phenylketonuria Medication Manufacturing Base Distribution and Headquarters
2.4 Key Companies Phenylketonuria Medication Product Offered
2.5 Key Companies Time to Begin Mass Production of Phenylketonuria Medication
2.6 Phenylketonuria Medication Market Competitive Analysis
2.6.1 Phenylketonuria Medication Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Phenylketonuria Medication Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Phenylketonuria Medication as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Kuvan
3.1.2 Palynziq
3.1.3 Others
3.2 Global Phenylketonuria Medication Sales Value by Type
3.2.1 Global Phenylketonuria Medication Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Phenylketonuria Medication Sales Value, by Type (2019-2030)
3.2.3 Global Phenylketonuria Medication Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Phenylketonuria Medication Sales Value by Application
4.2.1 Global Phenylketonuria Medication Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Phenylketonuria Medication Sales Value, by Application (2019-2030)
4.2.3 Global Phenylketonuria Medication Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Phenylketonuria Medication Sales Value by Region
5.1.1 Global Phenylketonuria Medication Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Phenylketonuria Medication Sales Value by Region (2019-2024)
5.1.3 Global Phenylketonuria Medication Sales Value by Region (2025-2030)
5.1.4 Global Phenylketonuria Medication Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Phenylketonuria Medication Sales Value, 2019-2030
5.2.2 North America Phenylketonuria Medication Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Phenylketonuria Medication Sales Value, 2019-2030
5.3.2 Europe Phenylketonuria Medication Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Phenylketonuria Medication Sales Value, 2019-2030
5.4.2 Asia Pacific Phenylketonuria Medication Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Phenylketonuria Medication Sales Value, 2019-2030
5.5.2 South America Phenylketonuria Medication Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Phenylketonuria Medication Sales Value, 2019-2030
5.6.2 Middle East & Africa Phenylketonuria Medication Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Phenylketonuria Medication Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Phenylketonuria Medication Sales Value
6.3 United States
6.3.1 United States Phenylketonuria Medication Sales Value, 2019-2030
6.3.2 United States Phenylketonuria Medication Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Phenylketonuria Medication Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Phenylketonuria Medication Sales Value, 2019-2030
6.4.2 Europe Phenylketonuria Medication Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Phenylketonuria Medication Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Phenylketonuria Medication Sales Value, 2019-2030
6.5.2 China Phenylketonuria Medication Sales Value by Type (%), 2023 VS 2030
6.5.3 China Phenylketonuria Medication Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Phenylketonuria Medication Sales Value, 2019-2030
6.6.2 Japan Phenylketonuria Medication Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Phenylketonuria Medication Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Phenylketonuria Medication Sales Value, 2019-2030
6.7.2 South Korea Phenylketonuria Medication Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Phenylketonuria Medication Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Phenylketonuria Medication Sales Value, 2019-2030
6.8.2 Southeast Asia Phenylketonuria Medication Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Phenylketonuria Medication Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Phenylketonuria Medication Sales Value, 2019-2030
6.9.2 India Phenylketonuria Medication Sales Value by Type (%), 2023 VS 2030
6.9.3 India Phenylketonuria Medication Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Biomarin
7.1.1 Biomarin Profile
7.1.2 Biomarin Main Business
7.1.3 Biomarin Phenylketonuria Medication Products, Services and Solutions
7.1.4 Biomarin Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.1.5 Biomarin Recent Developments
7.2 Vitaflo
7.2.1 Vitaflo Profile
7.2.2 Vitaflo Main Business
7.2.3 Vitaflo Phenylketonuria Medication Products, Services and Solutions
7.2.4 Vitaflo Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.2.5 Vitaflo Recent Developments
7.3 Mead Johnson
7.3.1 Mead Johnson Profile
7.3.2 Mead Johnson Main Business
7.3.3 Mead Johnson Phenylketonuria Medication Products, Services and Solutions
7.3.4 Mead Johnson Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.3.5 Nutricia Recent Developments
7.4 Nutricia
7.4.1 Nutricia Profile
7.4.2 Nutricia Main Business
7.4.3 Nutricia Phenylketonuria Medication Products, Services and Solutions
7.4.4 Nutricia Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.4.5 Nutricia Recent Developments
7.5 Abbott
7.5.1 Abbott Profile
7.5.2 Abbott Main Business
7.5.3 Abbott Phenylketonuria Medication Products, Services and Solutions
7.5.4 Abbott Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.5.5 Abbott Recent Developments
7.6 Dr. Schär
7.6.1 Dr. Schär Profile
7.6.2 Dr. Schär Main Business
7.6.3 Dr. Schär Phenylketonuria Medication Products, Services and Solutions
7.6.4 Dr. Schär Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.6.5 Dr. Schär Recent Developments
7.7 Prominmetabolics
7.7.1 Prominmetabolics Profile
7.7.2 Prominmetabolics Main Business
7.7.3 Prominmetabolics Phenylketonuria Medication Products, Services and Solutions
7.7.4 Prominmetabolics Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.7.5 Prominmetabolics Recent Developments
7.8 Cambrooke
7.8.1 Cambrooke Profile
7.8.2 Cambrooke Main Business
7.8.3 Cambrooke Phenylketonuria Medication Products, Services and Solutions
7.8.4 Cambrooke Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.8.5 Cambrooke Recent Developments
7.9 Juvela
7.9.1 Juvela Profile
7.9.2 Juvela Main Business
7.9.3 Juvela Phenylketonuria Medication Products, Services and Solutions
7.9.4 Juvela Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.9.5 Juvela Recent Developments
7.10 Firstplay Dietary
7.10.1 Firstplay Dietary Profile
7.10.2 Firstplay Dietary Main Business
7.10.3 Firstplay Dietary Phenylketonuria Medication Products, Services and Solutions
7.10.4 Firstplay Dietary Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.10.5 Firstplay Dietary Recent Developments
7.11 PKU Perspectives
7.11.1 PKU Perspectives Profile
7.11.2 PKU Perspectives Main Business
7.11.3 PKU Perspectives Phenylketonuria Medication Products, Services and Solutions
7.11.4 PKU Perspectives Phenylketonuria Medication Revenue (US$ Million) & (2019-2024)
7.11.5 PKU Perspectives Recent Developments
8 Industry Chain Analysis
8.1 Phenylketonuria Medication Industrial Chain
8.2 Phenylketonuria Medication Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Phenylketonuria Medication Sales Model
8.5.2 Sales Channel
8.5.3 Phenylketonuria Medication Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer